3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
9
Melanoma
4
Ganglioneuroblastoma
4
Triple Negative Breast Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Transplant-Related Hematologic Malignancy
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
Paclitaxel
7
Cyclophosphamide
6
Doxorubicin
5
pembrolizumab
3
Trastuzumab
3
Taxes
3
Specimen Handling
3
Carboplatin
3
pertuzumab
2
eribulin
2
Radiotherapy
2
Epirubicin
2
Docetaxel
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
ruxolitinib
1
pegfilgrastim
1
onvansertib
1
olaparib
1
neratinib
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Tamoxifen
1
Surgical Procedures, Operative
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
sargramostim
×
1 year
×
Clear all
No trials found.